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cal OncoSeveral major hospitals in Lombardy, Italy, recorded a striking
number of admissions for the COVID-19 disease - severe acute res-
piratory syndrome coronavirus 2 (SARS-CoV-2) starting in February
2020. The resulting shortage of medical and nursing staff, the rapid
reorganization and repurposing of surgical units into intensive care
units, the saturation levels of hospital bed occupancy, and the logis-
tical impossibility of isolating COVID-19 clinical pathways to ensure
patient safety throughout the emergency, rendered other hospital
activities unsustainable.
At the time of writing, our Breast Unit has been recognized by
Italy's Lombardy Regional Authorities as a “hub” center for breast
cancer treatment during the pandemic emergency health system
reorganization, providing continuity of care for patients whose
treatment cannot be delayed. Several months are expected to
elapse before the hospitals can revert to routine activities.
We report the experience of the first month of this new epoch in
our Breast Surgery Division, with a new “established and evolving”
routine.
The use of personal protective equipment is required for every
operative procedure performed. In the operating rooms, the anes-
thetists, surgeons and scrub nurses wear FFP2 N95 or FFP3 masks,
surgical caps, surgical gowns, double gloves, and protective visors.
A system of “smart working” from home has been activated, and
hospital attendance is limited to the necessary staff. Patients, staff
and visitors must wear a surgical mask and are required to pass
through a temperature checkpoint. Patients can access the hospital
only for scheduled appointments, and a telephone triage is per-
formed to guarantee safety. Only one visitor per patient can access
the hospital ward at an established time, except for outpatients in
need of assistance.
Balancing the risks of tumor progression and the risk of expo-
sure to COVID-19 [1], breast surgeries are selected according to
the paragraph Priorities for Breast Disease: Surgical Oncology [2]Respiratory Syndrome
on for Cancer Surgery, and the Eue table Priorities for Breast Cancer Disease Focused Surgi-
logy [3]. We have been able to ensure high, high/medium
and medium priority; briefly, we only schedule for surgery cases
whosewaiting time has been established to be less than 30 days ac-
cording to the National Health System regulations (invasive and
extensive high-grade in situ breast cancer, surgical complications).
Apart from patients for whom neoadjuvant treatment would have
been a standard option or elderly patients with comorbidities,
our policy has been not to prescribe primary endocrine therapy
to delay primary surgery, in contrast with other experiences [4].
Intraoperative evaluation of surgical margins, retroareolar tis-
sue, and sentinel nodes is performed to prevent the risk of reinter-
vention but only when strictly necessary, to protect the pathology
staff from risks.
Staff meetings and multidisciplinary case discussions are orga-
nized as video conference calls or e-mail.
Surgical clinical studies can be continued if no additional hospi-
tal appointments for patients are required.
Outpatient clinic activity is limited to urgent referrals, newly
diagnosed breast cancer cases, recurrences, necessary postopera-
tive appointments (i.e. drain removal). Telemedicine is employed
for postoperative oncological and radiotherapeutic indications
and an official report sent by e-mail.
According to the regional regulations, private practice is sus-
pended, and appointments are guaranteed to patients with a
referral from their General Practitioner. Patients can still be covered
by private insurance for surgical treatment to access private
facilities.
From 9th March 2020, when the government imposed a na-
tional quarantine, we considered four weeks of breast surgery ac-
tivity. We performed 370 interventions, with a 20% increase
compared to the same four weeks in 2019. The number of patients
from Lombardy doubled compared to that from the same period in
2019. An overall reduction of 87% was recorded in breast surgery
outpatient clinical activity, with only 274 accesses compared to
2020 accesses in 2019 (an 84% reduction of extra-regional patients
and a 42% reduction of patients from Lombardy). A total of 44 pa-
tients already scheduled for surgery in six other Breast Units
were transferred to us by direct regional request.
So far, we have yet to report any COVID-19 affected patients
among our admissions. Only one case was detected and isolated
at home after pre-admission. Two of our breast surgeons were
found to be infected from external sources, and no infections
have been detected in our Unit two weeks after their quarantine
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